top of page
cerrozone warson deck img3.png

Micron Pure™, LLC

A Hecto Group™ Company

THE TECHNOLOGY POWERING

cerrozone-logo-01-01.png
jj-ying-236821-unsplash.jpg

HERE TO STAY

According to CDC, there are now multiple COVID  variants circulating globally.


Ultraviolet light (UVC, UVB, UVA wavelengths) radiation causes mutations across the COVID genomes analyzed worldwide


The intensity and length exposure to the UV light within the CerroZone device will eliminate the virus and will not cause virus mutation

uv-sars-cov-2.png

The B.1.1.7 mutated version quickly became the most  common version of COVID in the UK, accounting for  about 60% of new COVID cases in December of 2020


Preliminary scientific evidence points to new variants,  including B.1.1.7, binding more tightly to human cells

VIRUS MUTATION

With 24% of the US population not planning to be vaccinated and eight COVID-19 variants already emerging, the US can expect to continue to feel the impacts of COVID-19 throughout 2021 and beyond.

The effectiveness of currently authorized vaccines against  these and new coronavirus variants is still being determined.

Variants of concern show evidence of increased transmissibility, more severe disease, significant reduction in antibodies or vaccine effectiveness and diagnostic detection failures.

 

covidvariants.png

Variants of interest show significant reduction in antibodies or vaccine effectiveness and diagnostic detection failures.

The B.1.617.2 delta variant is about 225% more transmissible than the original virus strain, and currently represents over 31% of U.S. cases.

As of July 16th, new cases of COVID-19 are up about 70%, and hospitalizations have risen about 36% across the U.S.

Experts worry the rise of the delta variant may force a return to stricter social distancing and masking protocols.

Rises in cases might also prevent kids from returning to school, as COVID-19 vaccines are not yet authorized for children under 12 years old.

FOR MORE THAN COVID

Since 2010, an average of 35,900 and 49,336 people in the US die from influenza and bacterial pneumonia 

​

Micron Pure ™ technology, CerroZone, is effective against all viruses, including influenza, as well as bacteria and other pathogens.


Independent lab studies proved the efficacy of Micron Pure ™ technology on the MS2 bacteriophage, a surrogate for both the coronavirus and the influenza virus.


The CDC estimates that the influenza virus is responsible for up to 810,000 hospitalizations and 61,000 deaths each year.


According to the American Journal of Medicine, the economic cost of influenza ranges between $3B to $5B per year.
 

OUR TECHNOLOGY

Innovative ozone technology eliminates all pathogens indoors including COVID-19, influenza, common cold viruses, and bacteria.

Filing for FDA 510(k) Class II medical instrument status.

Proven 99.999957% effective in independent trials.

Designed for all indoor spaces - schools, hospitals, businesses, churches, subways, buses, trains, hotels, airplanes.

Four patents filed; initiatives leading to 95+ patents in 19 countries.

US air purification demand is projected to reach $2.2B by 2024, growing 12.3% annually.


Highly fragmented air purification market composed of more than 50 manufacturers and filter producers – no dominant contenders.

cerrozoneunit.png

A POWERFUL SOLUTION

Micron Pure™ ozone technology powers CerroZone™ to eliminate the COVID-19 virus, influenza and common cold viruses, bacteria as well as odors.

  • Quickly and safely eliminates airborne viruses,  pathogens, and other harmful particles.

  • Ozone’s disinfecting power is about 3,000x faster than bleach.

  • Allows businesses, schools, hospitals – all  public  spaces to operate with reduced risk.

  • Prohibits virus genomes mutation.

pathogens.png
o3oxidation.png

“Ozone is very effective  at inactivating viruses. Within seconds, ozone  solubilizes the lipid membrane of the virus”

Source: Former Director for the Center for Disease Control (CDC),  Dr. Paul Meechan PhD, MPH, RPB, CBSP, SM(NRCM)

pattern1_edited.jpg
influ.png
bottom of page